The company’s growth trajectory has accelerated significantly since its first appearance on the list in 2024 at No. 1,765, followed by a No. 265 ranking in 2025. By maintaining a 1,017% growth rate through 2025, the firm outperformed the Inc. 5000 median of 130% by a substantial margin. CEO Dave Huffman attributed the performance to a broader shift in consumer interest, noting that the market is increasingly prioritizing science-backed approaches to healthy aging and longevity.
STEMREGEN Marks Third Year on Inc. 5000 List with 1,017% Growth
A 1,017% revenue surge over three years has secured Whitefish-based STEMREGEN the No. 332 spot on the 2026 Inc. 5000 list. This achievement marks the third consecutive year the stem cell supplement firm has appeared in the ranking, signaling sustained demand for products focused on the body’s innate repair mechanisms.
Founded by stem cell scientist Christian Drapeau, MSc, the company centers its product line on plant-based supplements. These formulas aim to facilitate the natural release, circulation, and migration of stem cells from bone marrow into tissues. As interest in regenerative health expands among athletes and the general wellness community, the company’s focus on endogenous stem cell mobilization continues to find a receptive audience in a competitive independent business sector.
Comments (0)
No comments yet. Be the first!